Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2625)	1/30/2019 2:33:20 AM
From: Miljenko Zuanic	Read Replies (2) of 3557

From Novartis, Lucentis ex-US 4Q sale were $520M (I had 510M in my book), so Eylea ex-US sale should be ~$685M, or global sale of $~6.7B. For 2019 projection is +$7B in Eylea global sale. CMS PartB Eylea 2017 spending is not yet out, but after today conference on drug spending it is obvious that NONE knows what is broken and how to fix it. So, for 2019 and most likely for 2020 not a big changes in Rx cost control (Eylea global sale) could be expected.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next